The study by Khamashita et al. evaluates the efficacy of warfarin, low-dose aspirin, or both in preventing recurrent thrombosis in patients with the antiphospholipid-antibody syndrome. The antiphospholipid-antibody syndrome is a thrombophilic disorder characterized by the presence of antiphospholipid antibodies, which can lead to venous or arterial thrombosis. The study included 147 patients (84% female) with a history of thrombosis, of whom 101 (69%) experienced a total of 186 recurrences. The median time between the initial thrombosis and the first recurrence was 12 months. Treatment with high-intensity warfarin (INR ≥3) with or without low-dose aspirin (75 mg/day) was significantly more effective in preventing further thrombotic events compared to low-intensity warfarin (INR <3) or aspirin alone. The highest rate of recurrence (1.30 per patient-year) occurred during the first six months after discontinuing warfarin therapy. Complications from bleeding occurred in 29 patients during warfarin therapy, with seven cases being severe. The study concludes that long-term anticoagulation therapy with an INR of 3 or higher is advisable for patients with the antiphospholipid-antibody syndrome to prevent recurrent thrombosis.The study by Khamashita et al. evaluates the efficacy of warfarin, low-dose aspirin, or both in preventing recurrent thrombosis in patients with the antiphospholipid-antibody syndrome. The antiphospholipid-antibody syndrome is a thrombophilic disorder characterized by the presence of antiphospholipid antibodies, which can lead to venous or arterial thrombosis. The study included 147 patients (84% female) with a history of thrombosis, of whom 101 (69%) experienced a total of 186 recurrences. The median time between the initial thrombosis and the first recurrence was 12 months. Treatment with high-intensity warfarin (INR ≥3) with or without low-dose aspirin (75 mg/day) was significantly more effective in preventing further thrombotic events compared to low-intensity warfarin (INR <3) or aspirin alone. The highest rate of recurrence (1.30 per patient-year) occurred during the first six months after discontinuing warfarin therapy. Complications from bleeding occurred in 29 patients during warfarin therapy, with seven cases being severe. The study concludes that long-term anticoagulation therapy with an INR of 3 or higher is advisable for patients with the antiphospholipid-antibody syndrome to prevent recurrent thrombosis.